Pembrolizumab in Combination with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Clinical Evidence, Regulatory Approval and Therapeutic Implications
Scientific Journal of Genetics and Gene Therapy · 2026 · 12 (1) · 001-003
DOI: 10.17352/sjggt.000025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Journal of Genetics and Gene Therapy, 2026. Verfasst von Sulaiman Naseer. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Background
Primary peritoneal carcinoma, fallopian tube cancer, and platinum-resistant epithelial ovarian cancer are aggressive cancers with few treatment choices and a dismal prognosis. In a variety of solid malignancies, immune checkpoint medications that target the programmed death receptor-1 (PD-1) have demonstrated encouraging activity.
Objectives
To examine the clinical effectiveness, safety, and therapeutic implications of pembrolizumab in combination with paclitaxel, with or without bevacizumab, for platinum-resistant ovarian cancers that express programmed death-ligand 1 (PD-L1). This approval was recently made by the US Food and Drug Administration (FDA).
Methods
Reviewed KEYNOTE-B96 (NCT05116189) clinical trial data, prescription information, and regulatory announcements. Progress-free survival (PFS) and overall survival (OS), as determined by the RECIST v1.1 criteria, were key effectiveness goals.
Results
PFS was 8.3 months in the pembrolizumab arm and 7.2 months in the placebo arm for patients with PD-L1 combination positive score (CPS) ≥1 (HR 0.72; p = 0.0014). 18.2 months and 14.0 months, respectively, were the median OS (HR 0.76; p = 0.0053). The safety profile aligned with immune-related side effects linked to PD-1 inhibitors that have been documented before.
Conclusion
The treatment of platinum-resistant ovarian tumors has advanced clinically with the approval of pembrolizumab in combination therapy. PD-L1 CPS-based biomarker-driven patient selection improves precision oncology methods and could lead to better survival rates in this high-risk group.
Zitieren
APA
Naseer, S. (2026). Pembrolizumab in Combination with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Clinical Evidence, Regulatory Approval and Therapeutic Implications. Scientific Journal of Genetics and Gene Therapy, 12(1), 001-003. https://doi.org/10.17352/sjggt.000025
Vancouver
Naseer S. Pembrolizumab in Combination with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Clinical Evidence, Regulatory Approval and Therapeutic Implications. Scientific Journal of Genetics and Gene Therapy. 2026;12(1):001-003. doi:10.17352/sjggt.000025
BibTeX
@article{Naseer2026,
author = {Naseer, Sulaiman},
title = {Pembrolizumab in Combination with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Clinical Evidence, Regulatory Approval and Therapeutic Implications},
journal = {Scientific Journal of Genetics and Gene Therapy},
year = {2026},
volume = {12},
number = {1},
pages = {001--003},
doi = {10.17352/sjggt.000025}
}
EUVIMED